The FINANCIAL -- AstraZeneca announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Tagrisso (osimertinib) for the 1st-line treatment of patients with inoperable or recurrent epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC), following priority ...

The FINANCIAL -- The U.S. Food and Drug Administration (FDA) recently finalized guidance to help biopharmaceutical manufacturers communicate about their products with payers, to support value-based ...

The FINANCIAL -- Patients on Aimovig (erenumab) in clinical trials reported consistent and sustained migraine prevention, with many experiencing a 50% or more reduction in monthly migraine days; ...

The FINANCIAL -- The end of the ninth outbreak of Ebola in the Democratic Republic of the Congo (DRC) is marked. The World Health Organization (WHO) congratulates the country and all those involved ...

The FINANCIAL -- Boston, MA – People who gain weight after they quit smoking may face a temporary increase in the risk of developing type 2 diabetes, with the risk directly proportional to the ...

The FINANCIAL -- ViiV Healthcare announced positive headline results from its global, phase III ATLAS study of a long-acting, injectable two-drug regimen (2DR) for the treatment of ...